CSF1R inhibition can reduce deleterious microglial proliferation and modulate microglial phenotypes during neuroinflammatory pathogenesis, particularly in progressive MS (Hagan et al., 2020). This evidence concerns the gene CSF1R and myeloid sarcoma.